The results were formally presented at the prestigious American Society for Radiation Oncology (ASTRO) Annual Meeting held in San Francisco, further highlighting their importance to the wider medical research community. The trial enrolled 193 evaluable patients in the proton therapy arm, offering a robust sample size to assess clinical outcomes rigorously. The biological basis underlying these clinical outcomes is rooted in the distinct physical and dosimetric properties of proton therapy. This trial also highlights the evolving landscape of radiation oncology, where advanced technologies such as intensity-modulated proton therapy (IMPT) enable more precise treatment delivery. Keywords:Glioblastoma, Proton Therapy, Radiation Dose Escalation, Temozolomide, Overall Survival, Lymphopenia, Intensity-Modulated Radiation Therapy (IMRT), Phase II Clinical Trial, NRG Oncology, Immunotherapy, Brain Cancer, Radiation Toxicity